CEO & Majority Shareholder Inject $12.9M via ATM, Extending Cash Runway Amidst Increased R&D
PLSE sits 85% above its 52-week low of $12.56.
Summary
Pulse Biosciences secured $12.9 million from its majority shareholder and CEO via an ATM offering, extending its cash runway and demonstrating strong insider confidence despite an increased net loss in Q1 2026.
Key Events · Financing and Capital Events · PLSE
-
Insider Capital Injection
Majority shareholder Robert Duggan and CEO Paul LaViolette purchased 675,233 shares for $12.9 million through an at-the-market (ATM) offering on May 11, 2026, demonstrating strong insider conviction.
-
Extended Cash Runway
The $12.9 million capital raise, combined with existing resources, is expected to fund operating activities for at least one year, addressing near-term liquidity concerns.
-
Increased R&D Investment
Research and development expenses increased by $2.3 million to $12.6 million in Q1 2026, reflecting continued strategic investment in the nPulse Cardiac Catheter and Surgical Clamp programs.
-
First Product Revenue Reported
The company reported its first product revenue of $0.4 million in Q1 2026 from the limited market release of its Vybrance Percutaneous Electrode System.
Analysis · PLSE · Industrial Applications And Services
Pulse Biosciences reported Q1 2026 financials showing an increased net loss and cash burn, but also its first product revenue of $0.4 million. Critically, the company announced a $12.9 million capital injection from its majority shareholder and Co-Chairman, Robert Duggan, and CEO and Co-Chairman, Paul LaViolette, through an at-the-market (ATM) offering. This insider purchase significantly bolsters the company's liquidity, extending its cash runway for at least one year. The increased R&D expenses reflect continued investment in its core Nano-pulse Stimulation (NPS) technology, particularly the nPulse Cardiac Catheter and Surgical Clamp programs, which have shown compelling clinical data.
At the time of this filing, PLSE was trading at $23.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.